On August 21, Dong-E-E-Jiao (000423) released its semi-annual report for 2024, showing that the company achieved revenue of approximately USD 3.76 billion in the first half of the year, an increase of 26.8% year-on-year. The net profit attributable to shareholders reached approximately USD 100.9 million, a year-on-year increase of 39.03%. Source: Dong-E-E-Jiao
Dong-E-E-Jiao Co., Ltd., formerly SHAN DONG DONG-E E-JIAO CO., LTD, is a China-based company principally engaged in the research, development, production and sale of traditional Chinese medicines of Ejiao and Ejiao series products. The Company distributes its Ejiao and Ejiao series products under the brand name of Dong-E E-Jiao. The Company is also involved in the production and sale of medical instrument and pharmaceutical excipients, as well as pharmaceutical trading business. The Company operates its business in domestic market, with East China and South China as its main markets.
Sign Up to Receive China Updates Weekly Newsletter for FREE, HERE
Visit HPA-China’s Information Hub, HERE